Default company panoramic image
Logo

Manresana de Micobacteriologia, s.l.

MANREMYC® is a company devoted to the development of Nyaditum resae®, a natural probiotic able to protect against active tuberculosis.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location NW Manresa Ct, Portland, OR, US
  • Currency EUR
  • Founded February 2013
  • Employees 1
  • Website manremyc.cat

Company Summary

MANREMYC® is a "spin off" company devoted to the development of Nyaditum resae®, a natural probiotic, able to protect against TB according to the research carried at the TB Unit of the Institut Germans Trias i Pujol (IGTP), in Badalona (Catalonia, Spain). The objectives to obtain a quality product ready to be transfered; to obtain additional data on safety and confirmatory proof of concept in humans; and to commercialize the product.

Team

  • Default avatar
    Pere-Joan Cardona

    Obtains the MD in 1992; Especiality in Clinical Microbiology in 1997 and PhD in Experimental Tuberculosis in 1999. Head of the Experimental Tuberculosis Unit since 1997. In 2000 start the investigation of a TB vaccine (RUTI) and patents it on 2003. Is one of the funders of Archivel Farma, becoming its CSO since 2005. RUTI is actually in Phase III clinical trial. He is the inventor of Nyaditum resae®.

  • Default avatar
    Isabel Amat

    Chemist, after this work in biotechnology, he has been the Chief Operating Officer of the RUTI® development, being co-inventor and co-founder of Archivel Farma. He was the responsible for the production and quality development of RUTI under GMP conditions, before starting to lead the development of other new biological under the company “Reig Jofre Biological Service” since 2010.

  • Default avatar
    Jaume Amat

    Engineer, he was a co-founder of Archivel Farma, and its first CEO, until 2008, when he started his own company to support the development of new biotechnology start-ups (Bioempren), and also another company devoted to the development of pigs and mini-pigs for research puroposes (Specipig).

  • Default avatar
    Cristina Vilaplana

    MD and specialist in Clinical microbiology, she joined the Unitat de Tuberculosi Experimental, where she obtained her PhD on 2010 after a thesis devoted to the study of the immunological profile of the therapeutic vaccine RUTI in the Phase I clinical trial. As a post-doc she has remained at the UTE, and has supported the development of the new theory on the induction of active TB. She is a co-inventor of the Nyaditum resae®.

Advisors

  • Default avatar
    Ignasi Costas
    Lawyer
    Unconfirmed
    Default avatar
    Xavier Oliveras
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    None
    Unconfirmed